<head>
<title>Core Laboratories N.V. 8K Earnings Release</title>
</head>

<html>

<body>

<b><font SIZE="2">
</font><font SIZE="4">
<p ALIGN="CENTER">UNITED STATES</p>
<p ALIGN="CENTER">SECURITIES AND EXCHANGE COMMISSION</p>
</font><font SIZE="2">
<p ALIGN="CENTER">Washington, D.C. 20549</p>
</font></b><font SIZE="2">
<p ALIGN="CENTER">________________</p>
</font><b><font SIZE="5">
<p ALIGN="CENTER">FORM 8-K</p>
</font></b>
<p ALIGN="CENTER"><center>
<div align="center">
  <center>
<table CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="684">
  <tr>
    <td VALIGN="TOP">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td VALIGN="TOP"><font SIZE="2">
      <p>CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
      EXCHANGE ACT OF 1934</font></td>
  </tr>
  <tr>
    <td VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td VALIGN="MIDDLE"><font SIZE="2">
      <p ALIGN="CENTER">Date of report:<b> November 20, 2006  </b></font></td>
  </tr>
  <tr>
    <td VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
</table>
  </center>
</div>
</center><font SIZE="2">
<p>&nbsp;</p>
<p>&nbsp;</p>
</font><b><font FACE="Times" SIZE="5">
<p ALIGN="CENTER">CORE LABORATORIES N.V.</p>
</font></b><font SIZE="2">
<p ALIGN="CENTER">(Exact name of registrant as specified in its charter)</p>
<p ALIGN="CENTER"><b>001-14273<br>
</b>(Commission File Number)</p>
</font>
<p ALIGN="CENTER"><center>
<div align="center">
  <center>
<table CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="680">
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">The Netherlands</font></b></td>
    <td WIDTH="49%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">Not Applicable</font></b></td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><font SIZE="2">
      <p ALIGN="CENTER">(State or other jurisdiction of incorporation or
      organization)</font></td>
    <td WIDTH="49%" VALIGN="MIDDLE"><font SIZE="2">
      <p ALIGN="CENTER">(I.R.S. Employer Identification No.)</font></td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="49%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">Herengracht 424</font></b></td>
    <td WIDTH="49%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">1017 BZ Amsterdam</font></b></td>
    <td WIDTH="49%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">The Netherlands</font></b></td>
    <td WIDTH="49%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">Not Applicable</font></b></td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><font SIZE="2">
      <p ALIGN="CENTER">(Address of principal executive offices)</font></td>
    <td WIDTH="49%" VALIGN="MIDDLE"><font SIZE="2">
      <p ALIGN="CENTER">(Zip Code)</font></td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="49%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
</table>
  </center>
</div>
</center><font SIZE="2">
<p ALIGN="CENTER">Registrant's telephone number, including area code: <b>(31-20)
420-3191</b></p>
<p ALIGN="CENTER">&nbsp;</p>
<p ALIGN="left"><font SIZE="2">Check the appropriate below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions: </font></p>
<table CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="680" style="border-left-width: 0; border-top-width: 0; border-bottom-width: 0">
  <tr>
    <td WIDTH="44" style="border-style: none; border-width: medium">
    <p align="center">___</td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">
    <p class="MsoNormal"><font SIZE="2">Written communications
    pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</font></td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium">&nbsp;</td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium">
      <font SIZE="2">
      <p align="center">___</font></td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">
      <p class="MsoNormal"><font SIZE="2">Soliciting material
      pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium">&nbsp;</td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">
      &nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium"><font SIZE="2">
    <p align="center">___</font></td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">
      <p class="MsoNormal"><font SIZE="2">Pre-commencement
      communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR
      240.14d-2 (b))</font></td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium">&nbsp;</td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium"><font SIZE="2">
    <p align="center">___</font></td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">
    <p class="MsoNormal"><font SIZE="2">Pre-commencement
    communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR
    240.13e-4 (c))</font></td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium">
      &nbsp;</td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">
      &nbsp;</td>
  </tr>
</table>
<hr>
<p>
<b>Item 8.01  Other Events
</b>
</p>
</font>
<FONT FACE="Times New Roman" SIZE=2>
<P ALIGN="JUSTIFY">Core Laboratories N.V. ("Core Lab")  announced that the initial purchasers of the senior exchangeable notes due 2011 (the "Notes") of Core Lab's U.S.-based wholly owned subsidiary, Core Laboratories LP ("CLLP")  have exercised in full their right to purchase an additional $50 million in aggregate principal amount of Notes (the "Additional Notes") to cover over-allotments in the private offering.  The closing of the offering of the Additional Notes occurred on 17 November, 2006.</P>
</FONT><font SIZE="2">
<FONT FACE="Arial" SIZE=2><U>
</U></FONT><font SIZE="2" FACE="Times New Roman">
<P ALIGN="JUSTIFY">The Additional Notes were offered on the same terms as the initial closing, including increases to the size of the exchangeable note hedge transactions and the separate warrant transaction which effectively increases the exchange price of the Notes from approximately $94.76 under the terms of the Notes to $127.56 per share of Core Lab's Common Shares from the perspective of Core Lab, representing a 75% premium based on the last reported sales price on the New York Stock Exchange of $72.89 per share on 31 October, 2006, the date of pricing.  On a consolidated basis, Core Lab will pay approximately $7.0 million in connection with the amendment to the note hedge transactions and the warrant transactions, providing net proceeds to Core Lab on a consolidated basis of approximately $43 million.</P>
</font>
<FONT FACE="Arial" SIZE=3>
</FONT><font SIZE="2" FACE="Times New Roman">
<P ALIGN="JUSTIFY">Core Lab intends to use the proceeds of the issuance of Additional Notes net of the additional cost of the note hedge transactions for general corporate purposes, including future repurchases of Core Lab's common shares.</P>
</font>
<FONT FACE="Arial" SIZE=3>
<font SIZE="2" FACE="Times New Roman">
<P ALIGN="JUSTIFY">This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.  These securities will not be registered under the Securities Act of 1933 or any state securities laws, and unless so registered, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the securities Act of 1933 and applicable state securities laws.</P>
<font SIZE="2">
<b>
<p>Item 9.01 Financial Statements and Exhibits</p>
<table class="MsoNormalTable" style="width: 468.75pt" cellSpacing="0" cellPadding="0" width="625" border="0">
  <tr>
    <td style="width: 4%; padding: 0in" width="4%">&nbsp;</td>
    <td style="width: 4%; padding: 0in" width="4%">
    <p style="text-align: center" align="right"><font SIZE="2">(d)</font></td>
    <td style="width: 1%; padding: 0in" width="1%">&nbsp;</td>
    <td style="width: 91%; padding: 0in" width="91%"><i>
    <font SIZE="2">Exhibits</font></i></td>
  </tr>
</table>
</b>
<p>99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Press release issued on November 20, 2006*</p>
<p>* This exhibit is intended to be furnished and shall not be deemed &quot;filed&quot;
for purposes of the Securities Act of 1934, as amended.</p>
</font>
<P ALIGN="JUSTIFY">&nbsp;</P>
<font SIZE="2">
</font>
</font>
<P ALIGN="JUSTIFY"></P>
<font SIZE="2" FACE="Arial">
</font>
</FONT>

<b>
<p></p>
<hr>
<p ALIGN="CENTER">SIGNATURES</b></p>
<p>Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
</font>
<center>
<div align="right">
<table BORDER="0" CELLSPACING="0" WIDTH="635" cellpadding="0">
  <tr>
    <td WIDTH="47%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="5%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="40%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="47%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="5%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="48%" VALIGN="bottom" COLSPAN="5"><font SIZE="2">
      <p>Core Laboratories N.V.</font></td>
  </tr>
  <tr>
    <td WIDTH="47%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="5%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="40%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="47%" VALIGN="bottom"><font SIZE="2">
      <p>Dated: November 20, 2006</font></td>
    <td WIDTH="5%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="bottom"><font SIZE="2">
      <p>By</font></td>
    <td WIDTH="1%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="40%" VALIGN="bottom"><font SIZE="2">
      <p style="border-bottom-style: solid; border-bottom-width: 1">/s/ Richard L. Bergmark</font></td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="47%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="5%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="40%" VALIGN="bottom"><font SIZE="2">
      <p>Richard L. Bergmark</font></td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="47%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="5%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="40%" VALIGN="bottom"><font SIZE="2">
      <p>Chief Financial Officer</font></td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
  </tr>
</table>
</div>
</center><font SIZE="2">
<p>&nbsp;</p>
<hr>
<b>
<p ALIGN="CENTER">SECURITIES AND EXCHANGE COMMISSION<br>
Washington, D.C. 20549</b></p>
<b>
<p ALIGN="CENTER">CORE LABORATORIES N.V.<br>
EXHIBIT INDEX TO FORM 8-K</b></p>
<p ALIGN="left">&nbsp;</p>
<p ALIGN="left">&nbsp;</p>
<center>
<div align="left">
<table CELLSPACING="0" BORDER="0" WIDTH="570" cellpadding="0">
  <tr>
    <td WIDTH="22%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="75%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="22%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p>EXHIBIT NO.</font></b></td>
    <td WIDTH="3%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="75%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p>ITEM</font></b></td>
  </tr>
  <tr>
    <td WIDTH="22%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="75%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="22%" VALIGN="TOP"><font SIZE="2">
      <p>99.1</font></td>
    <td WIDTH="3%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="75%" VALIGN="TOP">
      <p><font SIZE="2">Press release issued on November 20, 2006*</font></td>
  </tr>
</table>
</div>
</center>
<p>* This exhibit is intended to be furnished and shall not be deemed &quot;filed&quot;
for purposes of the Securities Act of 1934, as amended.</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
</font>

</body>

</html>
[{"type": "8-K", "sequence": "1", "filename": "clb-8k_overallotmentoption.htm", "description": "8-K", "secsgml_size_bytes": 14037}]
{"company-data": {"conformed-name": "CORE LABORATORIES N V", "cik": "0001000229", "assigned-sic": "1389", "irs-number": "000000000", "state-of-incorporation": "P7", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-14273", "film-number": "061228469"}, "business-address": {"street1": "1017 BZ AMSTERDAM", "street2": "HERENGRACHT 424", "city": "THE NETHERLANDS", "state": "P7", "phone": "3124203191"}, "mail-address": {"street1": "6316 WINDFERN", "city": "HOUSTON", "state": "TX", "zip": "77040"}}
Core Laboratories N.V. 8K Earnings Release
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
      EXCHANGE ACT OF 1934
Date of report:
November 20, 2006
CORE LABORATORIES N.V.
(Exact name of registrant as specified in its charter)
001-14273
(Commission File Number)
The Netherlands
Not Applicable
(State or other jurisdiction of incorporation or
      organization)
(I.R.S. Employer Identification No.)
Herengracht 424
1017 BZ Amsterdam
The Netherlands
Not Applicable
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code:
(31-20)
420-3191
Check the appropriate below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
___
Written communications
    pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
___
Soliciting material
      pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
___
Pre-commencement
      communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
      240.14d-2 (b))
___
Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
    240.13e-4 (c))
Item 8.01  Other Events
Core Laboratories N.V. ("Core Lab")  announced that the initial purchasers of the senior exchangeable notes due 2011 (the "Notes") of Core Lab's U.S.-based wholly owned subsidiary, Core Laboratories LP ("CLLP")  have exercised in full their right to purchase an additional $50 million in aggregate principal amount of Notes (the "Additional Notes") to cover over-allotments in the private offering.  The closing of the offering of the Additional Notes occurred on 17 November, 2006.
The Additional Notes were offered on the same terms as the initial closing, including increases to the size of the exchangeable note hedge transactions and the separate warrant transaction which effectively increases the exchange price of the Notes from approximately $94.76 under the terms of the Notes to $127.56 per share of Core Lab's Common Shares from the perspective of Core Lab, representing a 75% premium based on the last reported sales price on the New York Stock Exchange of $72.89 per share on 31 October, 2006, the date of pricing.  On a consolidated basis, Core Lab will pay approximately $7.0 million in connection with the amendment to the note hedge transactions and the warrant transactions, providing net proceeds to Core Lab on a consolidated basis of approximately $43 million.
Core Lab intends to use the proceeds of the issuance of Additional Notes net of the additional cost of the note hedge transactions for general corporate purposes, including future repurchases of Core Lab's common shares.
This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.  These securities will not be registered under the Securities Act of 1933 or any state securities laws, and unless so registered, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the securities Act of 1933 and applicable state securities laws.
Item 9.01 Financial Statements and Exhibits
(d)
Exhibits
99.1        
Press release issued on November 20, 2006*
* This exhibit is intended to be furnished and shall not be deemed "filed"
for purposes of the Securities Act of 1934, as amended.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Core Laboratories N.V.
Dated: November 20, 2006
By
/s/ Richard L. Bergmark
Richard L. Bergmark
Chief Financial Officer
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
CORE LABORATORIES N.V.
EXHIBIT INDEX TO FORM 8-K
EXHIBIT NO.
ITEM
99.1
Press release issued on November 20, 2006*
* This exhibit is intended to be furnished and shall not be deemed "filed"
for purposes of the Securities Act of 1934, as amended.